| Autor: |
Bunpei Isoda, Masanobu Shiga, Shuya Kandori, Yoshiyuki Nagumo, Takayuki Yoshino, Atsushi Ikeda, Takashi Kawahara, Tomokazu Kimura, Hiromitsu Negoro, Akio Hoshi, Bryan J Mathis, Hiroyuki Nishiyama |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Case Reports in Oncology, Vol 16, Iss 1, Pp 414-418 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
1662-6575 |
| DOI: |
10.1159/000530780 |
| Popis: |
Enfortumab vedotin (EV) is an antibody-drug conjugate and a promising agent for metastatic urothelial carcinoma (mUC). However, evaluations in end-stage renal disease patients undergoing hemodialysis are unreported. Here, we report such a case. A 74-year-old woman with mUC, on hemodialysis for complete urinary tract extirpation, was diagnosed with multiple pulmonary metastases after treatment with gemcitabine-carboplatin followed by pembrolizumab. As third-line therapy, she received a standard dose of EV. She achieved complete response after 2 cycles without grade 3 or higher adverse events, demonstrating the utility of EV in this setting. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
